<DOC>
	<DOCNO>NCT00064415</DOCNO>
	<brief_summary>The purpose study determine long-term safety arformoterol period 12 month subject COPD</brief_summary>
	<brief_title>To Evaluate Long-term Safety ( R , R ) -Formoterol Subjects With COPD</brief_title>
	<detailed_description>This multicenter , open-label , randomize , active control , parallel group chronic safety study arformoterol 50 mcg daily period 12 month subject COPD . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>INCLUSION CRITERIA : In order qualify participation , subject must meet following criterion : Must give write informed consent prior participation . Women childbearing potential must also sign Women Childbearing Potential Addendum . Must willing comply study procedure visit schedule Male female &gt; 35 year age Female subject &lt; 65 year age must serum pregnancy test conduct Visit 1 confirm negative prior randomization . Subjects childbearing potential must use acceptable method birth control . Female subject consider childbearing potential must : ( 1 ) document surgically sterile , OR ( 2 ) postmenopausal Have primary diagnosis COPD , may include component chronic bronchitis and/or emphysema . Diagnosis make screen process . Have minimum smoking history 15 packyears ( packyears = number cigarette pack per day time number year ) Medical Research Council ( MRC ) Dyspnea Scale Score &gt; 2 Have baseline FEV1 &lt; 65 % predict normal value &gt; 0.70 L document prior randomization Have FEV1/FVC ratio &lt; 70 % document prior randomization . Have chest xray consistent diagnosis COPD take &lt; 3 month prior Visit 1 . If chest xray take 3 month prior Visit 1 , chest xray perform prior Visit 2 . Be able complete study questionnaire log reliably EXCLUSION CRITERIA : In order qualify participation , subject must meet following criterion : Currently use disallow medication unable complete medication washout period Female subject pregnant lactating Have participate investigational drug study within 30 day prior Visit 1 currently participate another investigational drug study Subject whose schedule travel prevents completion require visit Subject schedule inpatient hospitalization , include elective surgery ( inpatient outpatient ) trial . Subject lifethreatening/unstable respiratory status , include upper low respiratory tract infection , within previous 30 day prior Visit 1 Known history asthma chronic respiratory disease ( include current history sleep apnea ) COPD ( chronic bronchitis and/or emphysema ) . Subject blood eosinophil count &gt; 5 % Subject clinically significant cardiac , hepatic , renal , gastrointestinal , endocrine , metabolic , neurologic , psychiatric disorder may interfere successful completion protocol History cancer except nonmelanomatous skin cancer History lung resection one full lobe Subject require continuous supplemental oxygen therapy . The use supplemental oxygen , exceed 2 L/minute , nighttime and/or exercise allow . Have change dose type medication COPD within 14 day prior screen visit Have know sensitivity ( R , R ) formoterol , ipratropium , salmeterol albuterol excipients contain formulation Have clinically significant abnormality may interfere metabolism excretion study drug Have history substance abuse drug abuse within 12 month Visit 1 positive urine drug screen screen visit Subject clinically significant abnormal laboratory value Subject clinically significant abnormal 12lead ECG may jeopardize subject 's ability complete study Subject use prescription drug concomitant betaagonist administration contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>